CAS: 183322-45-4; N-(3-Bromophenyl)-6,7-Dimethoxyquinazolin-4-Amine Hydrochloride
该化合物是上皮生长因子受体(EGFR)强力抑制剂的选择性强效抑制剂,其抗体抗体浓度约为25微米.它显示出EGFR的高度特异性,表明其针对其他动脉的活动极少,使其成为研究EGFR的中间信号路径的宝贵工具.盐的盐状可增强溶性和稳定性,确保生物化学和细胞测定的一致性能. PD1530335 氢化物被广泛用于研究癌症生物学的研究应用中,特别是在侧重于EGFR驱动的肿瘤产生和治疗抗药性的研究中,其特征清晰的抑制性特征和可靠性使它成为体外活性实验的首选.
- 英文名称N-(3-Bromophenyl)-6,7-Dimethoxyquinazolin-4-Amine Hydrochloride
- 中文名称4-[(3-溴苯基)氨基]-6,7-二甲氧基喹唑啉盐酸盐盐
- IUPAC名称N-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride
- 其它别名4-Quinazolinamine,N-(3-bromophenyl)-6,7-dimethoxy-, monohydr°Chloride (9CI); 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydr°Chloride
- CAS编号183322-45-4
- MFCD编号:MFCD01074805
- EINECS号:803-231-2
- FDA UNII编号:AHJ252P69N
- 分子式:C16H15BrClN3O2分子量:396.67
- 产品CID: 942670
- 同类组份化合物CAS153436-54-5 (free base)183322-45-4 (HCl)205195-07-9 (xHCl)586347-97-9 (nitrate)
- 产品分类生物化工 → 抑制剂 → 蛋白酪氨酸激酶
物理性质
- 熔点265 °C(文献)
- 沸点472.1 °C at 760 mmHg
- 闪点239.3 °C
- PSA:56.27
- LogP:5.0281
- 溶解性DMSO: Soluble2mg/mL, Clear (Warmed)
- 外观形态白色至米色粉末
- 储存条件密封, 常温干燥保存
- 产品应用该化合物用作:抑制A-431人类皮肤癌细胞(KI=5.2PM,IC50=29PM);有选择地阻塞瑞士3T3纤维体和A-43细胞(分别为IC50 = 15 NM和14 NM)中EGGFFR 诱发性亚化酶细胞线的扩散,包括A431,DIFI,DU145,MDA-M-MB-468和ME180(IC 50 = 022-0.95 ΜM);以依赖剂量的方式抑制NPC-TW01,NPCTW04和HONE1细胞线(IC50年=9.8-18.6微克/M);废除PAR(2) 磁性硫化物2-NHI-GRUFI-NULI-MUI-T-MOL-MLIFM)
MSDS等安全信息
- GHS象形图
- GHS符号GHS06 & GHS05;
注释: Skull and crossbones & Corrosion - 危险类别急性毒性 类别3(经口)
特定目标器官毒性 - 单次接触 类别3
皮肤腐蚀/刺激 类别2
严重眼损伤 类别1
水生慢性毒性 类别4 - 警示词Danger(危险)
- 危险描述H301 |吞咽会中毒.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H318 |造成严重眼损伤.
H413 |可能对水生生物造成长期有害影响. - 防范说明P280-P301+P310+P330-P302+P352-P305+P351+P338+P310
- UN编号UN 2811 6.1 / PGIII
- 危险品标志T
- 安全声明26-39-45
- 危险类别码25-37/38-41
- WGK Germany3
欧盟法规
C&L通报合成工艺路线路线简述
海关参考信息
- 2905110000-甲醇
2907210001-间苯二酚
2908199090-其他酚的卤化衍生物
2908999090-其他酚的硝化衍生物 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-11406709-B2
优先权日:2014-09-15
标 题 :Therapeutic and research application of PDCL3
发明人：RAHIMI NADER
权利人:UNIV BOSTON
摘要:Described herein are novel compositions comprising, for example, PDCL3 polypeptides having VEGFR-2 inhibitory activity, inhibitory PDCL3 antibodies and PDCL3-binding fragments thereof, or PDCL3 inhibitory nucleic acid molecules, and methods of their use in anti-angiogenesis and anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, as well as the treatment of those vascular diseases where pathological angiogenesis plays a role, such as in carotid artery disease, macular degeneration, and plaque neovascularization. Also described herein are novel compositions comprising engineered PDCL3 polypeptides having enhanced chaperone activity, recombinant cells comprising such engineered PDCL3 polypeptides having enhanced chaperone activity, and methods thereof for therapeutic protein production and in vitro protein synthesis.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Alagawani S, Vasilyev V, Clayton AHA, Wang F. Insights into Halogen-Induced Changes in 4-Anilinoquinazoline EGFR Inhibitors: A Computational Spectroscopic Study. Molecules. 2024 Jun 12;29(12):2800. doi: 10.3390/molecules29122800.
2: Xu P, Yang L, Lai S, Yang F, Kuroda Y, Zhang H, Tsuruta D, Katayama I. Effects of EGFR-TKI on epidermal melanin unit integrity: Therapeutic implications for hypopigmented skin disorders. Pigment Cell Melanoma Res. 2024 Jul;37(4):514-529. doi: 10.1111/pcmr.13171. Epub 2024 May 5. 49(5):1347-1358. doi: 10.1007/s11064-024-04122-y. Epub 2024 Feb 14.
95:104767. doi: 10.1016/j.ebiom.2023.104767. Epub 2023 Aug 24.
合成参考文献
参考文献:10.1007/s11010-020-04046-5
摘要:Suzuki S, Yuan H, Hirata-Tsuchiya S, Yoshida K, Sato A, Nemoto E, Shiba H, Yamada S. DMP-1 promoter-associated antisense strand non-coding RNA, panRNA-DMP-1, physically associates with EGFR to repress EGF-induced squamous cell carcinoma migration. Molecular and Cellular Biochemistry. 2021 Jan 09;476(4):1673–90. doi: 10.1007/s11010-020-04046-5.
📝 需求与反馈
尽可能描述清楚需求与问题信息
